Cargando…

State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic

The emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants made emerging novel coronavirus diseases (COVID-19) pandemic/endemic/or both more severe and difficult to manage due to increased worry about the efficacy and efficiency of present preventative, therapeutic, and sensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharjee, Rahul, Dubey, Ankit Kumar, Ganguly, Archisha, Bhattacharya, Basudha, Mishra, Yogendra Kumar, Mostafavi, Ebrahim, Kaushik, Ajeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463543/
http://dx.doi.org/10.1016/j.onano.2022.100078
_version_ 1784787414052503552
author Bhattacharjee, Rahul
Dubey, Ankit Kumar
Ganguly, Archisha
Bhattacharya, Basudha
Mishra, Yogendra Kumar
Mostafavi, Ebrahim
Kaushik, Ajeet
author_facet Bhattacharjee, Rahul
Dubey, Ankit Kumar
Ganguly, Archisha
Bhattacharya, Basudha
Mishra, Yogendra Kumar
Mostafavi, Ebrahim
Kaushik, Ajeet
author_sort Bhattacharjee, Rahul
collection PubMed
description The emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants made emerging novel coronavirus diseases (COVID-19) pandemic/endemic/or both more severe and difficult to manage due to increased worry about the efficacy and efficiency of present preventative, therapeutic, and sensing measures. To deal with these unexpected circumstances, the development of novel nano-systems with tuneable optical, electrical, magnetic, and morphological properties can lead to novel research needed for (1) COVID-19 infection (anti-microbial systems against SARS-CoV-2), (2) early detection of mutated SARS-CoV-2, and (3) targeted delivery of therapeutics using nano-systems, i.e., nanomedicine. However, there is a knowledge gap in understanding all these nano-biotechnology potentials for managing mutated SARS-CoV-2 on a single platform. To bring up the aspects of nanotechnology to tackle SARS-CoV-2 variants related COVID-19 pandemic, this article emphasizes improvements in the high-performance of nano-systems to combat SARS-CoV-2 strains/variants with a goal of managing COVID-19 infection via trapping, eradication, detection/sensing, and treatment of virus. The potential of state-of-the-art nano-assisted approaches has been demonstrated as an efficient drug delivery systems, viral disinfectants, vaccine productive cargos, anti-viral activity, and biosensors suitable for point-of-care (POC) diagnostics. Furthermore, the process linked with the efficacy of nanosystems to neutralize and eliminate SARS-CoV-2 is extensively highligthed in this report. The challenges and opportunities associated with managing COVID-19 using nanotechnology as part of regulations are also well-covered. The outcomes of this review will help researchers to design, investigate, and develop an appropriate nano system to manage COVID-19 infection, with a focus on the detection and eradication of SARS-CoV-2 and its variants. This article is unique in that it discusses every aspect of high-performance nanotechnology for ideal COVID pandemic management.
format Online
Article
Text
id pubmed-9463543
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-94635432022-09-10 State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic Bhattacharjee, Rahul Dubey, Ankit Kumar Ganguly, Archisha Bhattacharya, Basudha Mishra, Yogendra Kumar Mostafavi, Ebrahim Kaushik, Ajeet OpenNano Article The emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants made emerging novel coronavirus diseases (COVID-19) pandemic/endemic/or both more severe and difficult to manage due to increased worry about the efficacy and efficiency of present preventative, therapeutic, and sensing measures. To deal with these unexpected circumstances, the development of novel nano-systems with tuneable optical, electrical, magnetic, and morphological properties can lead to novel research needed for (1) COVID-19 infection (anti-microbial systems against SARS-CoV-2), (2) early detection of mutated SARS-CoV-2, and (3) targeted delivery of therapeutics using nano-systems, i.e., nanomedicine. However, there is a knowledge gap in understanding all these nano-biotechnology potentials for managing mutated SARS-CoV-2 on a single platform. To bring up the aspects of nanotechnology to tackle SARS-CoV-2 variants related COVID-19 pandemic, this article emphasizes improvements in the high-performance of nano-systems to combat SARS-CoV-2 strains/variants with a goal of managing COVID-19 infection via trapping, eradication, detection/sensing, and treatment of virus. The potential of state-of-the-art nano-assisted approaches has been demonstrated as an efficient drug delivery systems, viral disinfectants, vaccine productive cargos, anti-viral activity, and biosensors suitable for point-of-care (POC) diagnostics. Furthermore, the process linked with the efficacy of nanosystems to neutralize and eliminate SARS-CoV-2 is extensively highligthed in this report. The challenges and opportunities associated with managing COVID-19 using nanotechnology as part of regulations are also well-covered. The outcomes of this review will help researchers to design, investigate, and develop an appropriate nano system to manage COVID-19 infection, with a focus on the detection and eradication of SARS-CoV-2 and its variants. This article is unique in that it discusses every aspect of high-performance nanotechnology for ideal COVID pandemic management. The Author(s). Published by Elsevier Inc. 2022 2022-09-10 /pmc/articles/PMC9463543/ http://dx.doi.org/10.1016/j.onano.2022.100078 Text en © 2022 The Author(s). Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Bhattacharjee, Rahul
Dubey, Ankit Kumar
Ganguly, Archisha
Bhattacharya, Basudha
Mishra, Yogendra Kumar
Mostafavi, Ebrahim
Kaushik, Ajeet
State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic
title State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic
title_full State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic
title_fullStr State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic
title_full_unstemmed State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic
title_short State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic
title_sort state-of-art high-performance nano-systems for mutated coronavirus infection management: from lab to clinic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463543/
http://dx.doi.org/10.1016/j.onano.2022.100078
work_keys_str_mv AT bhattacharjeerahul stateofarthighperformancenanosystemsformutatedcoronavirusinfectionmanagementfromlabtoclinic
AT dubeyankitkumar stateofarthighperformancenanosystemsformutatedcoronavirusinfectionmanagementfromlabtoclinic
AT gangulyarchisha stateofarthighperformancenanosystemsformutatedcoronavirusinfectionmanagementfromlabtoclinic
AT bhattacharyabasudha stateofarthighperformancenanosystemsformutatedcoronavirusinfectionmanagementfromlabtoclinic
AT mishrayogendrakumar stateofarthighperformancenanosystemsformutatedcoronavirusinfectionmanagementfromlabtoclinic
AT mostafaviebrahim stateofarthighperformancenanosystemsformutatedcoronavirusinfectionmanagementfromlabtoclinic
AT kaushikajeet stateofarthighperformancenanosystemsformutatedcoronavirusinfectionmanagementfromlabtoclinic